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Background/aim: To evaluate the effect of the long-term use of systemic immunosuppressive drugs on druse formation in patients aged
over 50 years.
Materials and methods: The current retrospective cohort study includes 420 eyes of 420 patients. 210 eyes of 210 patients who used
immunosuppressive drugs (Group 1) at least for the last 5 years and 210 eyes of 210 control patients (Group 2) who did not use any
drugs were compared. All patients were older than 50 years and selected among patients who were followed by rheumatology and
ophthalmology clinic at a tertiary university hospital. All patients had complete ophthalmic examination, fundus photography and
optical coherence tomography (OCT). The primary outcome of this study is the difference in macular and paramacular druse formation
rates between two groups.
Results: Small, intermediate, large, soft, and paramacular druse formation rates were significantly lower in Group 1 than those in Group
2 (P = 0.028, P = 0.001, P = 0.001, P = 0.001, and P = 0.001, respectively).
Conclusion: Patients who used long-term systemic immunosuppressive drugs had significantly lower hard and soft druse formation
rate than age and sex matched control subjects.
Keywords: Druse, systemic immunosuppression, inflammation, age-related macular degeneration

1. Introduction
Globally, age-related macular degeneration (AMD)
accounts for 8.7% of all blindness cases and is the leading
cause of irreversible visual impairment among individuals
aged ≥65 living in developed countries [1,2]. AMD
is characterized by extracellular material, collectively
described as druse, which mostly accumulates under
the retina pigment epithelium (RPE). The mechanism
underlying the origin and growth of druse remains unclear.
Researches focused on lipids and minerals for druse
formation; however, there is relatively less information
regarding the origin of drusen associated proteins and how
they are retained in the space between the basal lamina of
the RPE and the inner collagenous layer. Considered to
be an early stage of AMD, druse formation involves the
accumulation of intracellular lipofuscin in the RPE and
the build-up of extracellular deposits under the RPE. It is
widely accepted that this local accumulation upregulates
cytokines and acute phase reactants, which activate the
complement cascade, and RPE and local cells respond to

the attack by complement proteins. Finally the dendritic
cells in the choroid invade incipient druse, and a strong
immune response is initiated against exposed antigens in
the sub-RPE [3]. While some authors suggest that druse
proteins primarily originate from the cellular debris of
the outer segment of processed photoreceptors and RPE,
others suggest a choroidal cell or blood-derived origin [4].
The commonly accepted pathological pathway involves
the oxidative modification of these lipids, resulting in
cross-linking of these molecules that leads to deposit and
subsequently druse formation. Local cellular damage at
the very early onset of AMD, via complement cascade
attack on druse proteins may lead to retinal damage and
more advanced AMD [5].
Many studies have reported on the outcomes of treated
or untreated AMD, including geographic atrophy or
choroidal neovascularization. Although drusen, regardless
of its subtypes, are widely accepted as the early finding
of AMD, the prevention and treatment of these lesions
remain unknown. Studies reported a correlation between
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complement system activation and AMD. This is based
on histological and proteomic data, showing complement
proteins in druse of postmortem eyes [6–8].
In the current study, we aimed to evaluate the effect
of long-term use of systemic immunosuppressive drugs
on druse formation and subsequently, the impact of
antiinflammation on the formation of these early lesions.
2. Methods
This study was conducted in accordance with the tenets of
the Declaration of Helsinki and was approved by the Local
Ethical Committee of the same research hospital. This is
a retrospective cohort study, and the participants were
selected among the patients visiting the rheumatology
and ophthalmology clinic of a tertiary referral clinic from
Turkey. Systemic immunosuppressive drug users were
chosen among patients who were sent to ophthalmology
clinic for fundus examination before initiation of the
treatment to rule out any contraindication for use of
systemic immunosuppressive drugs and to confirm the
absence of any drusen. All patients were Caucasian.
Control group patients were chosen among the patients
who had visited ophthalmology clinic and in the last 10
years who had no druse. Their mean follow-up duration
was (7.1 ± 1.3 years). All study and control patients had
fundus photographs within ten years before the study.
Patients who used immunosuppressive drugs for over 5
years were included in Group 1; age, sex-matched control
patients with no history of immunosuppressive drug usage
or AMD were included in Group 2. Smoking more than 10
cigarettes a day, glaucoma, diabetic retinopathy and any
corneal lesions were among exclusion criteria. All patients
in the group 1 had rheumatoid arthritis or ankylosing
spondylitis for the last ≥5 (5–18) years. Complement
system activation was accepted as a risk factor of druse
formation. Therefore, we included only those patients
who used immunosuppressive drugs that inhibit the
complement system and cytokine activation including
azathioprine, cyclosporine, leflunomide, methotrexate,
and oral steroids.
We classified drusen as small (diameter, <63 µm),
intermediate (diameter, 63–125 µm), large (diameter, >125
µm), and soft (diameter, >125 µm with frequently more
ill-defined edges) [9].
Fundus photographs (Zeiss F-450) and optical
coherence tomography (Cirrus HD-OCT, Carl Zeiss
Ophthalmic System Inc., Zeiss-Humphrey, Dublin, CA,
USA) scans were obtained by two different retina specialist.
The only information available to the operators was the
age of the patients. The images were randomized to allow
each eye to be independently graded in accordance with
inclusion of a single eye from each patient/control. Druse
sizes were measured manually by the graders. Paramacular
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area was decided as retinal areas outside the clinical
macula which is accepted as 1.5 mm diameter around
fovea. Figure 1 shows a color fundus photo and an OCT
image of a large druse from Group 1. For quality control,
all images were graded by two graders; any difference was
resolved by a third, senior grader.
The primary outcomes included macular and
paramacular druse formation. Secondary outcome
measures included visual acuity, intraocular pressure
(IOP), cataract formation, and the mean time of
immunosuppressive drug use.
2.1. Statistical analysis
Data were expressed as means ± standard deviations
and medians. Data distribution was assessed using
the Kolmogorov–Smirnov test. For comparison of the
continuous and independent variables Mann–Whitney
U test was used. For comparison of categorical variables
(especially evaluation of druse and cataract formation,
hypertension, family history, cigarette smoking) the chisquare test was used. A p value of <0.05 was accepted as
statistically significant. Statistical analysis was performed
using a licensed statistical software (IBM SPSS version
22.0; IBM Corp., Armonk, NY, USA).
3. Results
This cross-sectional study included 420 eyes of 420
patients: Group 1 comprised 210 eyes of 210 patients, and
group 2 comprised 210 eyes of 210 patients. The age of
the patients was over 50 years in both the groups, and the
median age was 61 (61.8 ± 5.8) years.
The small, intermediate, large, soft, and paramacular
druse formation rates were significantly lower in Group
1 than those in Group 2 (P = 0.028, P = 0.001, P =
0.001, P= 0.001, and P = 0.001, respectively). Druse
formation rates in both groups were given in Figure 2.
The table shows druse formation status and systemic
effects between the two groups. Mean follow up time of
the groups was 7.2 ± 1.9 (5–10) years. The mean time
of immunosuppressive drug use among the patients in
Group 1 was 7.1 ± 1.9 years. In Group 1, the mean age of
the patients who developed any type of drusen was 56.7 ±
4.6 (57–63) years, and mean drug use time was 5.2 ± 1.2
(5–8) years, which is significantly shorter than those who
used immunosuppressive drugs and developed no druse
7.3 ± 1.9 (5–10) years (P = 0.01). In Group 2, there was
no patients who used immunosuppressive drugs and the
mean age of patients who developed any type of drusen
was 57.2 ± 3.2 (52–64) years.
There was no statistically significant difference between
the groups regarding age and sex (P = 0.052 and P = 1.0,
respectively). Smoking rates of the groups were similar.
Cigarette smoking rate in Group 1 was 23.8% (50\210),
while 27.1 % (57\210) of Group 2 was smoking at most 10

SEVER and MERCAN / Turk J Med Sci

Figure 1. Colour fundus photo and optical coherence tomography of a large macular druse
from Group 1.

Figure 2. The druse formation rates of the groups. Group 1: the patients who
used systemic immunosuppressive drugs, Group 2: control group who did not
use any systemic immunosuppressive drugs.

pieces of cigarette (P = 0.543). IOP of group 1 (14.4 ± 1.6
mmHg) was significantly higher than that of group 2 (13.9
± 1.3 mmHg; P = 0.001). However, none of the patients
had glaucoma. Overall, 42 eyes (10%) in Group 1 and 30
(7.1%) in Group 2 were pseudophakic (P = 0.23); 30 eyes
(14.2%) in Group 1 and 4 (1.9 %) in Group 2 had cataract;
and this difference was statistically significant (P = 0.001).
Eleven patients (2.9%) from Group 1 had a history of
uveitis. This low rate of uveitis might be a result of strong
immunosuppression since the beginning of diagnosis
of the diseases. In Group 1, 85 (40.1%), 150 (71.4%), 95
(45.2%), 92 (43.8%), and 71 patients (33.8%) were using
steroids, methotrexate, leflunomide, azathioprine, and
cyclosporine, respectively. Furthermore, 109 (66.1%) and
81 (38.5%) patients were using three and two different
immunosuppressive drugs, respectively. In each group,
more than one drug was used in the last ≥5 (7.1 ± 1.9)
years. Mean duration of drug usage was 5.7, 8.3, 4.1, 7.3,

and 5.8 years for steroids, methotrexate, leflunomide,
azathioprine, and cyclosporine, respectively.
4. Discussion
In this study, we show that systemic immunosuppression
had been associated in our patient cohort with both
slower hard and soft druse formation rates. There are
only a few studies which evaluate association of systemic
immunosuppressive drugs and druse formation.
Furthermore, in this study we focused on the efficacy
of any therapeutic agent in druse formation. Drusen
are accepted as the hallmark of AMD. However, several
questions remain unanswered, including the source
of origin of the druse protein; it is unclear whether
these proteins originate from the photoreceptors, RPE,
choroidal endothelium or circulating blood. Moreover, it is
unknown whether druse formation can be prevented. The
most accepted mechanism of druse formation involves the
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Table. A comparison of the groups for druse formation, basic characteristics and external effects.
Group 1

Group 2

P

Patient, n

210

210

1 X²

Age, mean ± sd

61.9 ± 6.0

60.8 ± 5.4

0.052 m

Sex, male, %

88

88 41.9%

1.000 X²

IOP, mmHg, mean ± sd

14.4 ± 1.6

13.9 ± 1.3

0.001m

Cigarette smoking (<10 pieces\day), %

50 23.8%

57 27.1%

0.543 X²

Family history, %

35 16.6%

40 19%

0.352 X²

Hypertension, %

48 22.8%

57 27.1%

0.412 X²

Small drusen, %

12 5.7%

25 11.9%

0.028 X²

Intermediate drusen,%

4 1.9%

41 19.5%

0.001 X²

Large drusen, %

0 0.0%

16 7.6%

0.001 X²

Soft drusen, %

1 0.47%

10 4.7%

0.001 X²

Paramacular drusen,%

2 0.95%

19 9.0%

0.001 X²

Cataract, %

30 14.2%

4 1.9%

0.001 X²

41.9%

: Mann–Whitney U test; X²: chi-square test; IOP: intraocular pressure; Group 1: the patients who
used immunosuppressive drugs; Group 2: control group who did not use any immunosuppressive
drugs.
m

thickening of the Bruch’s membrane with advancing age,
the membrane becomes increasingly impermeable to low
concentrations of waste products that begin to accumulate
in the sub-RPE space. Although age is an independent risk
factor of druse formation, inflammation has been reported
to accelerate this process [10]. Our results strongly suggest
that druse formation may result from local and/or systemic
inflammation and is not merely due to lipid deposition on
the thickened Bruch’s membrane.
There are two prominent genetic locations,
complement factor H (CFH) and age-related maculopathy
susceptibility 2 (ARMS2), which creates susceptibility to
AMD. The CFH gene encodes for complement factor H,
a glycoprotein that plays an integral role in the regulation
of the alternative complement pathway and thought to
be responsible from dry type AMD. The ARMS2 gene
triggers the complement system at the surface of retinal
monocytes and microglia by binding to the surface of the
apoptotic and necrotic cells and primarily responsible
from wet type AMD [10–13]. Both types of AMD are
strongly related with complement system activation. A
previous study reported that compared with low-risk eyes
(homozygous for Y402), high-risk eyes (homozygous for
the Y402H SNP) demonstrated greater C-reactive protein
(CRP) immunoreactivity in the choroid, particularly in
regions containing druse-like deposits [14]. Seddon et al.
demonstrated that CRP levels and CFH genotype were
independently associated with AMD risk [15]. A strong
inflammatory subject is smoking and increases the risk
of AMD for all CFH, ARMS2, and HtrA serine peptidase
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1 (HTRA1) genotypes [16,17]. These pathways show the
relevance of inflammation on AMD and compel us to find
a way to prevent inflammation. A recent study proposed
therapeutically targeting systemic properdin and therefore
ameliorating the alternative complement system with could
be effective to treat locally complement-mediated diseases
[18]. On the other hand, to the best of our knowledge, no
study till date has reported the effect of inflammation on
the pathway prior to druse formation as there exists no
predictive biomarker before druse formation.
Uveitis is a common manifestation of systemic
inflammatory diseases and it has been reported that
patients with uveitis have lower rate of druse formation.
Investigators report that this sparing from AMD in uveitis
might be a result of long-term immunomodulatory
treatment [19]. Besides in our study we report that the
duration of drug use was strongly correlated with lower
druse rates. The patients in Group 1, who used systemic
immunosuppressive drugs for a longer period had lower
druse formation rates. Recently some studies investigated
early-onset macular degeneration (EOMD) to determine
a predictive marker of early AMD and druse formation.
A study investigating EOMD in seven families reported
that the FHL-1 gene, which is suggested to be the
main regulator of complement cascade in the Bruch’s
membrane, causes complement turnover dysregulation in
the membrane, complement overactivation, and EOMD
development [20]. The age-related eye disease study
1 (AREDS1) reported that the antioxidants, vitamins
C, vitamin E, beta carotene, and zinc reduce the risk of
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progression to advanced AMD. The age-related eye disease
study 2 (AREDS2), which included 4203 patients from 82
clinics, reported that the addition of lutein + zeaxanthin,
omega-3 long-chain polyunsaturated fatty acids
[docosahexaenoic acid (DHA) + eicosapentaenoic acid
(EPA)] or lutein + zeaxanthin and DHA + EPA to the
AREDS1 formulation in the primary analyses did not
further reduce the risk of progression to advanced AMD
[21]. AREDS2 reported that lutein + zeaxanthin require
further investigation for their potential inclusion in the
AREDS supplements. The limitations of AREDS2 include
inadequate dose, inadequate duration of treatment, or
both. Currently, antioxidation seems to be the hallmark for
preventing the progression of dry AMD [16].
Systemic immunosuppressive drugs have different
effects on immune system and AMD. Corticosteroids
inhibit proinflammatory cytokines, decrease choroidal
permeability and lower vascular endothelium growth
factor (VEGF) levels [22]. Cyclosporine directly inhibits
T cells which play a crucial role in AMD pathogenesis
[23]. Leflunomide acts as an inhibitor of aryl hydrocarbon
receptor which is a ligand activated transcription factor
and plays a role in AMD pathogenesis [24]. Methotrexate
basically inhibits TNF-α synthesis and T lymphocyte
proliferation by means of reducing new purine and
pyrimidine synthesis [25,26]. Also there are many studies
about the effect of hypercholesterolemia and statin use
in AMD pathogenesis. Some of them reported that
hypercholesterolemia increased the rate of AMD and some
reported that statins lower the rate of AMD diagnosis
however there is still no certain proof in the literature
[27,28].
Between 2020 and 2040, AMD is estimated to
affect approximately 200 million people globally and
approximately 2.8 million in Europe; two-thirds of this
population will have neovascular AMD, requiring multiple
anti-VEGF treatments [2,29]. In accordance with the
previous studies, the optional number of intravitreal antiVEGF injection ranges between 8 and 11 in a year. In
contrast, in the real-world setting, the number of injections
is far lower with a maximum six injections per year [30,31].
A study assessing the cost-effectiveness of such treatments
in the United Kingdom reported the annual cost of
ranibizumab and aflibercept for AMD as €33,000 and €
31,000, respectively, and this cost is continuously increasing
[32]. On the other hand annual cost of a patient with
rheumatoid arthritis with anti-TNFs and/or methotrexate/
corticosteroids will be €39,000 for all systemic problems
[33]. Currently, especially for developing countries, we
either have to find new, cost-effective treatment solutions
or have to identify a way to prevent the disease.
Studies reported that rheumatoid arthritis and HLA-B27
positive diseases increase the AMD diagnosis [34, 35]. In
our study we report that the effect of immunosuppression

is not only confined with decreasing the increased risk of
AMD in these inflammatory diseases but also decreases
the risk of druse formation even compared with normal
population.
A study assessing the origin of druse proteins reported
that these proteins primarily originate from the blood
and less commonly from the RPE, photoreceptors, or
choroid [36]. We propose that if we can prevent systemic
drusenomics, we can lower druse formation. Our results
suggest that druse may not be limited to local lipofuscin
accumulation and is rather a result of oxidative stress,
which may be prevented using immunosuppressive drugs.
Patient characteristics, including family history, high
serum CRP levels and old age may be considered as the
potential risk factors of druse formation. These risk factors
could be considered to investigate the genetic tendency of
these patients toward the development of AMD; moreover,
it may be reasonable for patients with ophthalmological
signs and proved genetic tendency of AMD to undergo
low dose systemic immunosuppressive drug therapy. We
believe this will not only decrease costs but also decrease
morbidity.
Cataract formation of Group 1 was significantly higher
than the other group. Although 40 % of the patients in
Group 1 were on systemic steroids only 14.2% of them
developed cataract. IOP of the patients in Group 1 was
higher than Group 2 however no one developed glaucoma.
The major limitations of our study are absence of
fundus autoflourescence photos of the patients, and
retrospective study design.
In conclusion, immunoreactivity appears to be
the reason for druse and AMD formation and certain
immunosuppressive or immunomodulatory drugs
at a reasonable dose may prevent druse formation or
progression of AMD. Ocular side effects of the patients
were evaluated as reasonable. However, patients should
be careful about systemic side effects while using systemic
immunosuppressive drugs. This study needs to be further
supported by prospective and large-scale studies.
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